Skip to content

Study of Monochromatic X-ray Mammography System

Study of Monochromatic X-ray Mammography System

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07219797
Enrollment
52
Registered
2025-10-22
Start date
2026-06-01
Completion date
2027-04-01
Last updated
2026-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Breast Imaging

Keywords

Mammography

Brief summary

A research study to find out if an investigational mammography machine is effective in producing high-quality images using a lower radiation dose than traditional mammography.

Detailed description

Prospective, single-arm, non-blinded, comparative/observational study. Phase 1: Verify operation of monochromatic system and optimize the monochromatic energies and exposure times for a range of breast thicknesses. Phase 2: Test the performance of the monochromatic system in comparison to traditional 2-D mammography for a range of clinical/imaging scenarios. Phase 3: Test the performance of the monochromatic system using reduced breast compression.

Interventions

DEVICE2-D Monochromatic X-ray Mammography System

Monochromatic x-ray mammography system produces superior images as compared to conventional 2-D and 3-D mammography while using a lower radiation dose.

Sponsors

Imagine Scientific, Inc.
Lead SponsorINDUSTRY
Duke Health
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Female * 40 yrs of age or older * Capable of giving informed consent * Prior history of mammography

Exclusion criteria

* Pregnancy * History of breast cancer surgery, including lumpectomy or mastectomy * Currently undergoing treatment for breast cancer * Previous breast augmentations

Design outcomes

Primary

MeasureTime frameDescription
Noninferiority of a 2-D monochromatic X-ray mammography system compared to conventional mammographyEnrollment to end of visit 1 (or up to 7 days following visit 1, if needed)Demonstrate that a 2-D monochromatic X-ray mammography system can produce mammographic images using lower radiation dose (at least 20% less than conventional mammography), yet, not inferior to conventional mammography. \[Likert scale 1-3. Higher score is a better outcome\]

Secondary

MeasureTime frameDescription
Relevant pathologies identified by monochromatic-based x-ray as compared to conventional mammographyEnd of visit 1 (or up to 7 days following visit 1, if needed)Assess ability of monochromatic-based X-ray mammography to identify relevant pathologies in subjects with dense breast issue (BI-RADS density categories C and D) otherwise not detected in scans produced with conventional mammography. \[Likert scale 1-3. Higher score is a better outcome\]
Lower breast compression with monochromatic-based x-ray mammographyEnrollment to end of visit 1 (or up to 7 days following visit 1, if needed)Assess ability of monochromatic-based x-ray mammography to produce quality images with lower breast compression. \[Likert scale 1-3. Higher score is a better outcome\]
Quality of images produced by monochromatic-based x-ray mammography at lower radiation dose.Enrollment to end of visit 1 (or up to 7 days following visit 1, if needed)Demonstrate ability of monochromatic-based mammography to produce quality images at radiation doses below maximum FDA-approved radiation dose. \[Likert scale 1-3. Higher score is a better outcome\]
Patient satisfaction with monochromatic x-ray mammography systemEnrollment to end of visit 1 (or up to 7 days following visit 1, if needed)Assess patient satisfaction with monochromatic x-ray mammography system. \[Likert scale 1-5. Higher score is a better outcome.\]

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORLars Grimm, MD

Duke Health

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026